In contrast to the commonly adopted surveillance intervals in current abdominal aortic aneurysm screening programmes, surveillance intervals of several years may be clinically acceptable for the majority of patients with small aneurysms, as the smallest aneurysms often do not appear to change significantly over many years, according to a meta-analysis of previous studies reported in the 27 February issue of the Journal of the American Medical Association (JAMA).
With more than 100 patients enrolled, Cook Medical has exceeded 50 percent enrollment in the Tibiopedal Access for Crossing of Infrainguinal Artery Occlusions trial. The first-of-its-kind, prospective, multicenter study is evaluating the retrograde tibiopedal vascular access technique for treating critical limb ischemia (CLI), a manifestation of peripheral arterial disease (PAD).
The New England Journal of Medicine has published findings from the RE-MEDY and RE-SONATE trials investigating dabigatran etexilate (Pradaxa, Boehringer Ingelheim) in the long-term prevention of deep vein thrombosis (DVT) or pulmonary embolism (PE). The results demonstrate that Pradaxa 150mg twice daily is an effective option with a favourable safety profile for the extended prevention of recurrence of these venous blood clots after a first event.
Los bebés nacidos de mujeres obesas típicamente presentan un engrosamiento de un vaso sanguíneo clave del corazón que parece relacionares con el peso excesivo de sus madres
Bolton Medical has selected Expect Advertising for the launch of their new product, Relay Thoracic Stent-Graft. Expect Advertising will develop strategic planning, branding, ad campaign, website, tradeshow, collaterals, SEO, direct marketing, physician/patient education material, and other integrated marketing initiatives for the launch of Relay.
Endologix, Inc. (ELGX), developer and marketer of innovative treatments for aortic disorders, announced today achievement of the CE (Conformite Europeenne) Mark of the Nellix(R) EndoVascular Aneurysm Sealing System for the treatment of patients with abdominal aortic aneurysms ("AAA"). Nellix is the first available endovascular aneurysm sealing ("EVAS") system. EVAS with Nellix is an advanced treatment strategy designed to simplify endovascular AAA procedures, treat a broad range of patients, and provide enhanced clinical outcomes. The Nellix System is not approved in the United States for either investigational use or commercial sale.
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that data from the first prospective, multicenter, randomized clinical trial of a totally percutaneous approach (PEVAR) to endovascular abdominal aortic aneurysm repair (EVAR) was recently presented at two medical meetings. The presentation on the closure device independent substudy was made by Zvonimir Krajcer, MD (Program Director - Peripheral Vascular Interventions, Department of Cardiology, St. Luke s Episcopal Hospital at the Texas Heart Institute, Houston, TX) at the 25th Annual International Symposium on Endovascular Therapy (ISET), which took place January 19-23, 2013. The presentation on the PEVAR Trial primary analysis was made by Peter R. Nelson, MD, MS (Assistant Professor of Vascular Surgery at University of Florida, Gainesville, FL) at the 37th Annual Meeting of the Southern Association for Vascular Surgery (SAVS), which took place January 23-26, 2013.
Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the completion of patient enrollment in its iliac stent clinical study series. The series is composed of two prospective, multinational, multicenter studies - VISIBILITY Iliac and DURABILITY Iliac.
El uso de aspirina a largo plazo podría aumentar ligeramente el riesgo de desarrollar degeneración macular relacionada con la edad, una importante causa de ceguera entre las personas mayores, sugiere un estudio reciente.
Lombard Medical Technologies announced on 15 February 2013 that Aorfix has been approved for commercial sale in the USA by the FDA. Aorfix is the company’s flexible stent graft for the endovascular repair of abdominal aortic aneurysms. Data from the US PYTHAGORAS trial of Aorfix, has demonstrated that Aorfix can successfully treat a larger patient population than competing devices, including both standard and difficult to treat cases of abdominal aortic aneurysm.
Los diabéticos que se someten a una angioplastia coronaria primaria registran menos revascularizaciones del vaso tratado cuando se utilizan stents liberadores de fármacos (DES, por su sigla en inglés) en lugar de stents metálicos (BMS, por su sigla en inglés)
Konstantinos P Donas, Clinic for Vascular and Endovascular Surgery, Münster University Hospital and St Franziskus Hospital, Münster, Germany, and colleagues have found that the use of chimney and/or periscope endografts for pararenal aortic pathologies achieves and maintains successful exclusion of aneurysms in 90% of the cases at 24 months of radiological follow-up.
At the LINC congress (Leipzig, Germany, 23–26 January), Dierk Scheinert, Park Hospital Leipzig, Germany, presented the details of a new randomised controlled trial that will evaluate a drug-eluting stent vs. paclitaxel-eluting balloons for the treatment of symptomatic femoropopliteal artery disease.
With more than 100 patients enrolled,Cook Medical announced on 5 February 2013 it has exceeded 50% enrolment in the Tibiopedal Access for Crossing of Infrainguinal Artery Occlusions trial. The first-of-its-kind, prospective, multicentre study is evaluating the retrograde tibiopedal vascular access technique for treating critical limb ischaemia.
Medtronic has announced the CE mark and international launch of its Complete SE self-expanding vascular stent for use in the lower extremities, specifically, the superficial femoral arteries and proximal popliteal arteries.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos